Cp pharmaceuticals steroids

Valproic acid was first synthesized in 1882 by Beverly S. Burton as an analogue of valeric acid , found naturally in valerian . [66] Valproic acid is a carboxylic acid , a clear liquid at room temperature. For many decades, its only use was in laboratories as a "metabolically inert" solvent for organic compounds. In 1962, the French researcher Pierre Eymard serendipitously discovered the anticonvulsant properties of valproic acid while using it as a vehicle for a number of other compounds that were being screened for antiseizure activity. He found it prevented pentylenetetrazol -induced convulsions in laboratory rats . [67] It was approved as an antiepileptic drug in 1967 in France and has become the most widely prescribed antiepileptic drug worldwide. [68] Valproic acid has also been used for migraine prophylaxis and bipolar disorder. [69]

References: 1. BESIVANCE Prescribing Information, September 2012. 2. At 12 hours, the concentration of besifloxacin in tears was >10 µg/mL. Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharm Ther . 2009;25(4):335-344. 3. Comstock TL, Paterno MR, Usner DW, Pichichero ME. Efficacy and safety of besifloxacin ophthalmic suspension % in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Paediatr Drugs . 2010;12(2):105-112.

Prismic Pharmaceuticals is a specialty pharmaceutical company focused on the development of innovative prescription drugs with unique safety profiles to address pain and inflammation.

The company’s first prescription product candidate, PP101, (“micro-PEA”, being micronized palmitoylethanolamide with particle sizes of -10 micron), is in development for patients suffering from fibromyalgia as an adjunctive therapy to the current standard of care, specifically for those patients who are not achieving a satisfactory level of pain relief. 

The company has acquired the worldwide licensing rights (with
the exception of Italy and Spain) to a proprietary form of palmitoylethanolamide from which PP101 has been formulated.  Prismic has data indicating that when PP101 is administered concomitantly with treatments for severe chronic pain, such as pregabalin, duloxetine, or gabapentin or with narcotic analgesics/opiates, such as morphine, oxycodone, and hydrocodone, PP101 has a “potentiating” or “synergistic” effect on the other drug. As a result, the desired therapeutic effect can be achieved using a lower dose of the opiate or the effectiveness of other pain treatments such as pregabalin, duloxetine, or gabapentin, can be enhanced.

PP101 is protected by an extensive portfolio of issued and pending US and international patents  The patent portfolio covers micro-PEA, alone and in combination with other molecules, including, but not limited to, opioids, across a broad array of medical conditions. 

The company was founded in 2011 by industry veterans, Peter Moriarty (Warner-Lambert, Schering-Plough, and Shire Pharmaceuticals Co-Founder); Zachary Dutton (Laxdale, Efamol, Primus); and Danilo Casadei Massari (Fidia, and CM&D Founder, acquired by Nestle Health Sciences).

Cp pharmaceuticals steroids

cp pharmaceuticals steroids


cp pharmaceuticals steroidscp pharmaceuticals steroidscp pharmaceuticals steroidscp pharmaceuticals steroidscp pharmaceuticals steroids